Biobanking study to understand cancer and immune response
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
This study is collecting tumor and blood samples from cancer patients to see how their tumors and immune responses change during treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1050 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Curie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 6 sites (Bordeaux and 5 other locations) |
| Trial ID | NCT03017573 on ClinicalTrials.gov |
What this trial studies
This study collects tumor and blood samples from patients with various types of cancer, including ovarian, triple-negative breast, head and neck, cervical, and sarcoma. It aims to identify new molecular and immunological biomarkers that correlate with the clinical and biological characteristics of these tumors. Patients will undergo standard treatments while providing samples at multiple time points, such as before and after surgery and during chemotherapy. The goal is to better understand the link between tumor alterations, the tumor microenvironment, and the immune response.
Who should consider this trial
Good fit: Ideal candidates include adults with newly diagnosed, treatment-naïve ovarian, triple-negative breast, head and neck, cervical, or sarcoma cancers who are eligible for surgery or neoadjuvant chemotherapy.
Not a fit: Patients under 18 years old or those with conditions that may hinder compliance with the study protocol will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the discovery of new biomarkers that improve cancer treatment and patient outcomes.
How similar studies have performed: Other studies focusing on molecular and immunological biomarkers in cancer have shown promise, indicating that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Tumor types : 1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy 2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy 3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery 4. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2). 5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment 2. Male or female patients ≥ 18 years of age 3. Signed informed consent Exclusion Criteria: 1. Male or female patients ≤18 years old 2. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 3. Individually deprived of liberty or placed under the authority of a tutor 4. Patients not affiliated to the Social Security System
Where this trial is running
Bordeaux and 5 other locations
- Institut Bergonie — Bordeaux, France (Recruiting)
- Centre Oscar Lambret — Lille, France (Recruiting)
- Centre Leon Berard — Lyon, France (Recruiting)
- Institut Curie — Paris, France (Recruiting)
- Institut Curie Hopital Rene Huguenin — Saint-Cloud, France (Recruiting)
- Institut de Cancérologie de Lorraine - Nancy — Vandœuvre-lès-Nancy, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Edith BORCOMAN, Prof. — Institut Curie
- Study coordinator: Anne-Sophie PLISSONNIER
- Email: drci.promotion@curie.fr
- Phone: 01 47 11 23 78
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.